



- JPW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Longgui WANG et al.

Confirmation No.: 9273

Application No.: 10/754,547

Group Art Unit: 1614

Filing Date: January 12, 2004

Examiner: Donna A. Jagoe

For: METHODS OF TREATING AN  
INFLAMMATORY-RELATED DISEASE

Attorney Docket No.: 81481-300

**SECOND INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


Pursuant to Applicant's duty of disclosure under 37 C.F.R. § 1.56, enclosed is a Form PTO-1449 listing fourteen (14) references, copies of which are provided for the Examiner's convenience.

It is respectfully requested that the references be made of record in this application by the Examiner's completion and return of the attached Form PTO-1449.

This Second Information Disclosure Statement is filed under § 37 C.F.R. 1.97(b)(3), prior to the mailing of a first Office Action on the merits. Thus, no fee is believed to be due. However, the Commissioner is authorized to charge any fees which may be required to Winston & Strawn LLP Deposit Account No. 50-1814.

Respectfully submitted,


2/28/05  
\_\_\_\_\_  
Date

  
\_\_\_\_\_  
Rodney J. Fuller (Reg. No. 46,714)  
For: Allan A. Fanucci (Reg. No. 30,256)

**WINSTON & STRAWN LLP**  
Customer No. 28765

202-371-5904

<b>LIST OF REFERENCES CITED BY APPLICANT</b> <b>Form PTO-1449</b> <i>(Use several sheets if necessary)</i>	ATTY. DOCKET NO.: 81481-300	APPLICATION NO.: 10/754,547
	APPLICANT: Longgui WANG et al.	
Sheet 1 of 1	FILING DATE: January 12, 2004	GROUP: 1614



OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
C1	Cooper, J.C. et al. Alefacept selectively promotes NK cell-mediated deletion of CD45R0+ human T cells. Eur J Immunol, 33: 666-675, 2003.	
C2	Dayer, J. M. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology (Oxford), 42 Suppl 2: ii3-10, 2003.	
C3	Furlan, R., Pluchino, S., and Martino, G. Gene therapy-mediated modulation of immune processes in the central nervous system. Curr Pharm Des, 9: 2002-2008, 2003.	
C4	Haugeberg, G., Orstavik, R. E., and Kvien, T. K. Effects of rheumatoid arthritis on bone. Curr Opin Rheumatol, 15: 469-475, 2003.	
C5	Haboubi, N.Y. et al., "Radiation colitis is another mimic of chronic inflammatory bowel disease," J Clin Pathol, Vol. 45, p. 272 (1992)	
C6	Hochberg, M.C. et al., "Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis," Ann Rheum Dis, Vol. 62, Suppl 2, pp. ii13-ii16 (2003)	
C7	Hotamisligil, G.S. and Spiegelman, B. M. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes, 43: 1271-1278, 1994	
C8	Palladino, M. A., Bahjat, F. R., Theodorakis, E. A., and Moldawer, L. L. Anti-TNF-alpha therapies: the next generation. Nat Rev Drug Discov, 2: 736-746, 2003.	
C9	Robertson, J., Beaulieu, J. M., Doroudchi, M. M., Durham, H. D., Julien, J. P., and Mushynski, W. E. Apoptotic death of neurons exhibiting peripherin aggregates is mediated by the proinflammatory cytokine tumor necrosis factor-alpha. J Cell Biol, 155: 217-226, 2001.	
C10	Rutgeerts, P., Lemmens, L., Van Assche, G., Noman, M., Borghini-Fuhrer, I., and Goedkoop, R. Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther, 17: 185-192, 2003.	
C11	Schmidt, M. I. and Duncan, B. B. Diabetes: an inflammatory metabolic condition. Clin Chem Lab Med, 41: 1120-1130, 2003.	
C12	Virdis, A. and Schiffrin, E. L. Vascular inflammation: a role in vascular disease in hypertension? Curr Opin Nephrol Hypertens, 12: 181-187, 2003.	
C13	von der Thusen, J. H., Kuiper, J., van Berkel, T. J., and Biessen, E. A. Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol Rev, 55: 133-166, 2003.	
C14	Williams, J. D. and Griffiths, C. E. Cytokine blocking agents in dermatology. Clin Exp Dermatol, 27: 585-590, 2002.	

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	